Gastrointestinal effects
(iv) the prevention and/or treatment of cardiovascular disease, such as the delaying or reduction of the development of a major adverse cardiovascular event (MACE) selected from the group consisting of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularisation, hospitalisation for unstable angina pectoris, and hospitalisation for heart failure
[1] It is used as a diluent to dissolve or dilute medications for intravenous (IV), intramuscular (IM), or subcutaneous (SQ) injection according to the instructions of the specific drug being prepared
Originally developed to reduce excess abdominal fat in individuals with HIV, Tesamorelin has gained popularity for its ability to stimulate the release of growth hormone, which in turn helps reduce visceral fat and improve body composition
Delivered reconstituted, not in powdered form as seen when sourced from a lab
The trial concluded that AOD-9604 did not induce significant weight loss, leading to a halt in the development of the drug as a weight-loss solution